12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols
Key Takeaways
Postpartum Hemorrhage (PPH) is defined as cumulative blood loss >=1,000 mL OR blood loss accompanied by signs or symptoms of hypovolemia within 24 hours of birth, regardless of delivery route (vaginal or cesarean); visual estimation notoriously underestimates blood loss by 30% to 50%, mandating standardized quantitative blood loss (QBL) measurement.
Primary (early) PPH occurs within the first 24 hours and is driven by uterine atony in 70% to 80% of cases; secondary (late) PPH occurs between 24 hours and 12 weeks postpartum, most commonly precipitated by retained placental fragments, subinvolution, or endometritis.
The etiologies of PPH are categorized by the "4 Ts": Tone (uterine atony), Tissue (retained placenta, accreta spectrum), Trauma (lacerations, hematomas, uterine inversion/rupture), and Thrombin (consumptive or inherited coagulopathies).
Stepwise uterotonic pharmacotherapy requires strict respect for contraindications: methylergonovine (Methergine) is STRICTLY CONTRAINDICATED in hypertension or preeclampsia due to the risk of severe vasoconstriction and stroke; carboprost tromethamine (Hemabate) is STRICTLY CONTRAINDICATED in active asthma due to potent bronchoconstriction.
Tranexamic acid (TXA, 1 g IV over 10 minutes) must be administered within 3 hours of birth to reduce maternal mortality; refractory bleeding requires intrauterine balloon tamponade (Bakri balloon 300–500 mL), surgical compression sutures (B-Lynch), and activation of a Massive Transfusion Protocol (MTP) with a 1:1:1 ratio of PRBCs, FFP, and platelets.
Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols
Obstetric hemorrhage remains a leading cause of maternal morbidity and preventable maternal mortality worldwide. Effective management demands prompt recognition, standardized quantitative blood loss (QBL) assessment, and immediate algorithmic intervention across multidisciplinary care teams.
Modern Definition, Staging & Clinical Assessment of PPH
Revising historical bifurcated definitions (500 mL for vaginal delivery vs. 1,000 mL for cesarean), the American College of Obstetricians and Gynecologists (ACOG) and the California Maternal Quality Care Collaborative (CMQCC) establish a unified definition:
Postpartum Hemorrhage (PPH): Cumulative blood loss >=1,000 mL OR blood loss accompanied by signs or symptoms of hypovolemia (e.g., tachycardia, hypotension, tachypnea, oliguria, pallor, diaphoresis, altered sensorium) within 24 hours of birth, regardless of delivery route.
- Primary (Early) PPH: Occurs within the first 24 hours following delivery. Overwhelmingly caused by uterine atony (70%–80%).
- Secondary (Late) PPH: Occurs between 24 hours and 12 weeks postpartum. Most commonly caused by retained cotyledons or succenturiate lobes, subinvolution of the placental bed, or infection.
- Quantitative Blood Loss (QBL): Visual estimation of blood loss (EBL) underestimates actual hemorrhage by 30% to 50%. QBL replaces visual estimation through direct volumetric container measurement and gravimetric dry-weight subtraction (1 g = 1 mL) of blood-soaked sponges and drapes.
Etiologic Classification: The "4 Ts" Framework
Diagnostic evaluation rapidly proceeds through the classic "4 Ts" to identify and correct the underlying source of bleeding:
| Etiology ("T") | Frequency | Pathophysiologic Mechanisms & Clinical Manifestations | Specific Risk Factors & Management |
|---|---|---|---|
| Tone (Uterine Atony) | 70%–80% | Failure of the myometrium to contract firmly around spiral arteries. Uterus is soft, boggy, enlarged, and situated above the umbilicus. | Prolonged labor, oxytocin augmentation, chorioamnionitis, multiparity, uterine overdistension (macrosomia, polyhydramnios, multiples). Tx: Fundal massage, uterotonics. |
| Tissue (Retained Products) | 10%–20% | Retention of placental cotyledons, succenturiate lobe, or invasive placenta accreta spectrum (accreta, increta, percreta). | Previous cesarean delivery, placenta previa, manual removal. Tx: Manual exploration, bedside ultrasound, curettage with banjo curette. |
| Trauma (Lacerations & Inversion) | 15%–20% | Lacerations of the cervix, vagina, or perineum; pelvic hematomas; uterine rupture; uterine inversion. Firm, contracted uterus with persistent bright red bleeding. | Operative vaginal birth (forceps/vacuum), precipitous birth. Tx: Surgical repair; immediate manual replacement for uterine inversion. |
| Thrombin (Coagulopathies) | <1%–5% | Failure of clot formation due to pre-existing coagulopathy (von Willebrand disease, hemophilia) or consumptive coagulopathy (DIC). | Placental abruption, severe preeclampsia/HELLP syndrome, amniotic fluid embolism, sepsis. Tx: Fresh frozen plasma, platelets, cryoprecipitate. |
Stepwise Uterotonic Pharmacotherapy & Critical Contraindications
Active management of the third stage of labor (AMTSL)—prophylactic oxytocin administration, controlled cord traction, and uterine assessment—is standard for all deliveries. When uterine atony produces active PPH, uterotonics must be administered rapidly in a stepwise fashion:
| Uterotonic Agent | Standard Dose & Route | Mechanism of Action | Common Adverse Effects | Strict Contraindications & Warnings |
|---|---|---|---|---|
| Oxytocin (Pitocin) | 10–40 units IV in 500–1,000 mL crystalloid; or 10 units IM | Stimulates oxytocin G-protein receptors, inducing rhythmic myometrial contraction | Water intoxication with large volumes; transient flushing | Never administer as rapid undiluted IV bolus (causes severe hypotension, peripheral vasodilation, and cardiac arrest). |
| Methylergonovine (Methergine) | 0.2 mg IM every 2–4 hours (maximum 5 doses); may be given intramyometrial | Ergot alkaloid causing sustained, tetanic uterine smooth muscle contraction | Nausea, vomiting, headache, acute hypertension | STRICTLY CONTRAINDICATED in hypertension, preeclampsia, gestational hypertension, CAD, peripheral vascular disease (risk of stroke and MI). |
| 15-methyl PGF2-alpha (Carboprost / Hemabate) | 250 mcg (0.25 mg) deep IM or intramyometrial q15–90 min (max 8 doses / 2 mg) | Prostaglandin F2-alpha analog inducing intense myometrial contraction | Severe explosive diarrhea, fever, flushing, nausea, chills | STRICTLY CONTRAINDICATED in patients with active asthma or reactive airway disease (causes potent bronchospasm). |
| Misoprostol (Cytotec) | 800–1,000 mcg rectally OR 600–800 mcg sublingually/orally (single dose) | Synthetic prostaglandin E1 analog stimulating myometrial contraction | High-grade pyrexia (temp up to 40°C), severe shivering and rigors | Safe in hypertension and asthma. Useful when parenteral access is delayed or refrigerated drugs are unavailable. |
Tranexamic Acid (TXA) Protocol
Tranexamic acid is a synthetic lysine analog that competitively inhibits plasminogen activation, stabilizing fibrin clots. Based on the landmark international WOMAN trial (World Maternal Antifibrinolytic Trial):
- Dosing & Administration: 1 g IV diluted in 100 mL 0.9% normal saline infused over 10 minutes.
- Timing Window: Must be administered within 3 hours of birth. If given >3 hours post-delivery, mortality benefits are lost, and harm may occur.
- Repeat Dose: A second 1 g dose may be infused if bleeding persists after 30 minutes or recurs within 24 hours.
- TXA does not increase the risk of venous thromboembolism, myocardial infarction, or stroke when administered for obstetric hemorrhage.
Non-Pharmacologic, Tamponade & Surgical Interventions
When pharmacotherapy fails to arrest bleeding, advanced mechanical and surgical modalities must be deployed without delay:
- Bimanual Uterine Compression: The clinician inserts a gloved fist into the anterior vaginal fornix, pushing the anterior uterine wall upward, while the other hand compresses the posterior uterine wall through the abdominal wall.
- Intrauterine Balloon Tamponade (Bakri Balloon): A silicone balloon catheter is inserted transcervically into the uterine cavity and inflated with 300 to 500 mL of sterile isotonic saline. The balloon exerts hydrostatic counter-pressure exceeding capillary perfusion pressure, tamponading venous sinusoids. A vaginal gauze pack prevents balloon expulsion. The drainage port is monitored for active hemorrhage ("tamponade test"). The balloon remains in place for 12 to 24 hours before gradual deflation.
- Uterine Compression Sutures: Laparotomy allows placement of the B-Lynch brace suture (or modified Hayman/Pereira sutures) to exert vertical mechanical compression on the uterine fundus and lower segment.
- Surgical Vessel Ligation: Stepwise bilateral uterine artery ligation (O'Leary stitches) and internal iliac (hypogastric) artery ligation reduce pelvic arterial pulse pressure.
- Uterine Artery Embolization (UAE): Performed by interventional radiology in hemodynamically stable patients with secondary PPH or persistent oozing.
- Emergent Peripartum Hysterectomy: The definitive lifesaving procedure for intractable uterine atony, placenta accreta spectrum, or uterine rupture unresponsive to conservative measures.
Hemodynamic Resuscitation & Massive Transfusion Protocol (MTP)
In Stage 3 hemorrhage (>1,500 mL blood loss, vital sign instability, or suspected DIC):
- Establish two large-bore peripheral IV lines (14- or 16-gauge) or central venous access.
- Activate Massive Transfusion Protocol (MTP): Transfuse uncrossed O-negative blood until type-specific blood is available. Administer blood components in a balanced 1:1:1 ratio (1 unit Packed Red Blood Cells [PRBCs] : 1 unit Fresh Frozen Plasma [FFP] : 1 unit Platelets) to prevent dilutional coagulopathy.
- Fibrinogen Surveillance & Repletion: Maternal fibrinogen levels normally rise to 400–600 mg/dL during pregnancy. A fibrinogen level <200 mg/dL is a critical harbinger of catastrophic hemorrhage and DIC. Replete immediately with cryoprecipitate (10 units raises fibrinogen by ~100 mg/dL) or fibrinogen concentrate.
- Prevent the Lethal Triad: Actively prevent hypothermia (fluid warmers, forced-air warming blankets), acidosis (optimize tissue perfusion), and hypocalcemia (replace ionized calcium depleted by citrate preservatives in transfused blood).
A 34-year-old G3P3 at 38 weeks gestation with severe preeclampsia (blood pressure 166/108 mm Hg) delivers a 4,100 g infant vaginally. Five minutes following placental delivery, brisk vaginal bleeding is noted, and the uterine fundus is soft, boggy, and resting 3 cm above the umbilicus. Total cumulative blood loss has reached 1,150 mL. Bimanual uterine massage is initiated and an intravenous infusion of oxytocin (30 units in 500 mL lactated Ringer's) is running wide open, but uterine atony persists with continued brisk bleeding. Which of the following uterotonic medications is STRICTLY CONTRAINDICATED in this patient?
Carboprost tromethamine (Hemabate) 250 mcg IM.
Methylergonovine maleate (Methergine) 0.2 mg IM.
Misoprostol (Cytotec) 800 mcg sublingually.
Tranexamic acid (TXA) 1 g IV over 10 minutes.
A 29-year-old G2P1 at 40 weeks gestation experiences uterine atony following a rapid precipitous delivery. She has a medical history of moderate persistent asthma treated with a daily inhaled corticosteroid and as-needed albuterol inhaler. The obstetric team has already administered prophylactic and therapeutic intravenous oxytocin. The clinician prepares to administer the next line of uterotonic therapy. Which agent is strictly contraindicated due to her respiratory history?
Misoprostol 1,000 mcg given rectally once
Methylergonovine 0.2 mg IM every 2–4 hours
Tranexamic acid 1 g IV over 10 minutes
Carboprost (15-methyl PGF2-alpha) 250 mcg IM
A 31-year-old G1P0 undergoes an emergency cesarean delivery for fetal bradycardia following an abruption. Two hours post-op, her heart rate is 132 bpm, blood pressure drops to 78/42 mm Hg, and surgical suction plus peripads demonstrate a cumulative measured blood loss of 1,600 mL. Laboratory values reveal hemoglobin 6.8 g/dL, platelet count 48,000/μL, and fibrinogen 110 mg/dL. Point-of-care coagulation tests confirm consumptive coagulopathy. What is the most appropriate hemodynamic resuscitation strategy?
Activate massive transfusion with 1:1:1 red cells, plasma, and platelets, plus cryoprecipitate and tranexamic acid.
Infuse 4,000 mL of 0.9% normal saline through two large-bore IVs while withholding blood components until crossmatch is complete.
Administer 4 units of packed red blood cells as monotherapy and bolus 500 mL of 5% albumin solution.
Administer high-dose subcutaneous heparin to halt microvascular thrombi and transfuse single-donor platelets.
Sections you finish are checked off in the contents.